The Pharmaceutical Sciences and Pharmacogenomics Graduate Program (PSPG) is a cross-disciplinary program that consists of scientists at the University of California, San Francisco (UCSF) working in pharmaceutical sciences, computation and contemporary genetics. This Program encompasses the areas of molecular pharmacology related to drug development including: drug action, drug transport, drug metabolism and drug/gene delivery. The Program also includes the areas of pharmacokinetic/dynamic modeling, pharmacogenomics and bioinformatics applied to genetics/genomics. The Program offers training in these research areas through a core curriculum that encourages a breadth of knowledge about these fields and an elective curriculum that provides in-depth education on specific topics or techniques. Students participate in an ethical conduct in science course. The program immerses young scientists in the culture of science through a seminar program in pharmacogenomics, an annual retreat and seminars from industrial scientists. Students are recruited into the program with undergraduate degrees in the basic sciences and from Doctor of Pharmacy programs. There are 50 students in the program and approximately 10% of the students come from under represented groups. The program capacity was increased in 2000 from 35 students to 60 students and we anticipate reaching the 60 student capacity in 2012. There are 49 training faculty. Our program is one of the very few in the World with faculty expertise that spans the fields of pharmaceutics, genetics and computation;hence the training program is ideally situated to educate future scientific leaders in the emerging research areas at the intersection of these disciplines. The integrative approach has resulted in Ph.D. graduates who have the insights and quantitative scientific tools required for success in the rapidly advancing fields of drug development and pharmacogenomics;consequently graduates from the program are in high demand in academia, government and industry.
| Bielski, Craig M; Donoghue, Mark T A; Gadiya, Mayur et al. (2018) Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell 34:852-862.e4 |
| Soumerai, Tara E; Donoghue, Mark T A; Bandlamudi, Chaitanya et al. (2018) Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clin Cancer Res 24:5939-5947 |
| Zou, Ling; Stecula, Adrian; Gupta, Anshul et al. (2018) Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. Mol Pharmacol 94:689-699 |
| Donnella, Hayley J; Webber, James T; Levin, Rebecca S et al. (2018) Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nat Chem Biol 14:768-777 |
| Ivry, Sam L; Meyer, Nicole O; Winter, Michael B et al. (2018) Global substrate specificity profiling of post-translational modifying enzymes. Protein Sci 27:584-594 |
| Benet, Leslie Z; Bowman, Christine M; Liu, Shufang et al. (2018) The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. Pharm Res 35:242 |
| Park, Danny S; Eskin, Itamar; Kang, Eun Yong et al. (2018) An ancestry-based approach for detecting interactions. Genet Epidemiol 42:49-63 |
| Bielski, Craig M; Zehir, Ahmet; Penson, Alexander V et al. (2018) Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50:1189-1195 |
| Chang, Matthew T; Bhattarai, Tripti Shrestha; Schram, Alison M et al. (2018) Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discov 8:174-183 |
| Theofilas, Panos; Ehrenberg, Alexander J; Nguy, Austin et al. (2018) Probing the correlation of neuronal loss, neurofibrillary tangles, and cell death markers across the Alzheimer's disease Braak stages: a quantitative study in humans. Neurobiol Aging 61:1-12 |
Showing the most recent 10 out of 193 publications
